Real-world survival benefit of chemotherapy in elderly patients with advanced gastric cancer: a population-based SEER analysis.
OpenAlex 토픽 ·
Gastric Cancer Management and Outcomes
Helicobacter pylori-related gastroenterology studies
Economic and Financial Impacts of Cancer
APA
Nobuhiro Nakazawa, Kengo Kuriyama, et al. (2026). Real-world survival benefit of chemotherapy in elderly patients with advanced gastric cancer: a population-based SEER analysis.. Scientific reports. https://doi.org/10.1038/s41598-026-50084-2
MLA
Nobuhiro Nakazawa, et al.. "Real-world survival benefit of chemotherapy in elderly patients with advanced gastric cancer: a population-based SEER analysis.." Scientific reports, 2026.
PMID
42034813
같은 제1저자의 인용 많은 논문 (5)
- Minimally invasive versus open completion total gastrectomy for remnant gastric cancer: a nationwide propensity score-matched analysis.
- Identification of Biomarkers for Assessing Treatment Efficacy of Chemotherapy plus Nivolumab as the First Line in Patients with Unresectable Advanced or Recurrent Gastric Cancer: A Multicenter Study.
- Comprehensive genetic analysis of poorly differentiated gastric cancer in young females.
- Prognostic Nutrition Index as a Biomarker for Treatment Sensitivity to Chemotherapy and Nivolumab as the First-Line Treatment in Patients with Unresectable Advanced or Recurrent Gastric Cancer: A Multicenter Study.
- ASO Author Reflections: The Gustave Roussy Immune Score May Be a Useful Biomarker for Conversion Surgery After Chemotherapy Plus Nivolumab as the First-Line Treatment for Gastric Cancer.